Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN3 | Q9H6Z9 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | GPR139 | Q6DWJ6 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12727408 | 1.00 | EGLN3 (0.58) | EGLN3MEN1KMT2AEGLN1POLB | |
| SCHEMBL1640310 | 1.00 | EGLN3 (0.58) | EGLN3MEN1KMT2AEGLN1POLB | |
| SCHEMBL12727390 | 0.95 | EGLN3 (0.56) | EGLN3MEN1KMT2AEGLN1POLB | |
| SCHEMBL1640840 | 0.95 | EGLN3 (0.56) | EGLN3MEN1KMT2AEGLN1POLB | |
| SCHEMBL13568173 | 0.92 | EGLN3 (0.52) | EGLN3MEN1KMT2AEGLN1POLB | |
| SCHEMBL1641970 | 0.92 | EGLN3 (0.52) | EGLN3MEN1KMT2AEGLN1POLB | |
| SCHEMBL1644341 | 0.92 | EGLN3 (0.52) | EGLN3MEN1KMT2AEGLN1POLB | |
| SCHEMBL1642720 | 0.92 | EGLN3 (0.52) | EGLN3MEN1KMT2AEGLN1POLB | |
| SCHEMBL1642270 | 0.91 | EGLN3 (0.61) | EGLN3MEN1KMT2AEGLN1NPC1 | |
| SCHEMBL1642177 | 0.87 | EGLN3 (0.61) | EGLN3MEN1KMT2AEGLN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN2, EGLN3 | EGLN3 3/4885MEN1 3669/4885KMT2A 759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.